Vanguard Group Inc. Has $152.09 Million Holdings in AtriCure, Inc. $ATRC

Vanguard Group Inc. increased its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 1.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,714,371 shares of the medical device company’s stock after acquiring an additional 61,166 shares during the period. Vanguard Group Inc. owned about 9.52% of AtriCure worth $152,086,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Ameriprise Financial Inc. purchased a new stake in AtriCure in the 4th quarter valued at about $295,000. Envestnet Asset Management Inc. increased its stake in AtriCure by 22.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock valued at $1,828,000 after buying an additional 10,570 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in AtriCure by 5.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 146,096 shares of the medical device company’s stock valued at $4,713,000 after buying an additional 6,995 shares during the last quarter. GAMMA Investing LLC increased its stake in AtriCure by 9,664.9% in the 1st quarter. GAMMA Investing LLC now owns 3,613 shares of the medical device company’s stock valued at $112,000 after buying an additional 3,576 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in AtriCure in the 1st quarter valued at about $1,847,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Up 0.6%

AtriCure stock opened at $36.07 on Thursday. AtriCure, Inc. has a 1-year low of $23.27 and a 1-year high of $43.11. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -46.84 and a beta of 1.61. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. The firm has a 50 day simple moving average of $32.87 and a 200 day simple moving average of $33.97.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The business had revenue of $136.14 million during the quarter, compared to analyst estimates of $130.17 million. During the same period in the previous year, the business earned ($0.17) EPS. AtriCure’s revenue was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS. On average, analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total value of $91,450.00. Following the completion of the transaction, the insider directly owned 71,872 shares in the company, valued at approximately $2,629,077.76. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Regina E. Groves sold 2,452 shares of AtriCure stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the transaction, the director owned 33,715 shares of the company’s stock, valued at $1,241,386.30. This represents a 6.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,452 shares of company stock valued at $265,333 over the last quarter. 3.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. UBS Group decreased their price objective on shares of AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. JMP Securities reiterated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research note on Wednesday, April 30th. Finally, BTIG Research set a $54.00 price target on shares of AtriCure in a research note on Wednesday, July 30th. Nine investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $50.89.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.